|Dr. Nagesh K. Mahanthappa Ph.D., MBA||Pres, CEO & Exec. Director||N/A||N/A||1965|
|Ms. Erin Moore||Sr. VP of Fin. & Interim Principal Accounting Officer||N/A||N/A||N/A|
|Dr. Alan J. Buckler||Chief Scientific Officer||N/A||N/A||1960|
|Ms. Catherine Hu||Exec. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Junlin Ho||VP & Head of Corp. Legal||N/A||N/A||N/A|
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, an inhibitor of the activation of transforming growth factor beta-1 to treat cancers resistant to checkpoint blockade therapies. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corporation’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.